Related references
Note: Only part of the references are listed.Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein
Nai-Hsiang Chung et al.
VACCINE (2022)
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Kathryn E. Stephenson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity
Kenta Matsuda et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
Shiyu Sun et al.
CELL RESEARCH (2021)
Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice
Adrian Rice et al.
SCIENTIFIC REPORTS (2021)
Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study
David Liebowitz et al.
LANCET INFECTIOUS DISEASES (2020)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Feng-Cai Zhu et al.
LANCET (2020)
Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
Lynda Coughlan
FRONTIERS IN IMMUNOLOGY (2020)
The Global Phosphorylation Landscape of SARS-CoV-2 Infection
Mehdi Bouhaddou et al.
CELL (2020)
A protective bivalent vaccine against Rift Valley fever and bluetongue
Eva Calvo-Pinilla et al.
NPJ VACCINES (2020)
Live Oral Adenovirus Type 4 and Type 7 Vaccine Induces Durable Antibody Response
Natalie D. Collins et al.
VACCINES (2020)
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques
Liqiang Feng et al.
NATURE COMMUNICATIONS (2020)
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
Shipo Wu et al.
NATURE COMMUNICATIONS (2020)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Maheshi N. Ramasamy et al.
LANCET (2020)
Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus
Moritz U. G. Kraemer et al.
NATURE MICROBIOLOGY (2019)
T Follicular Helper Cell Biology: A Decade of Discovery and Diseases
Shane Crotty
IMMUNITY (2019)
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine
Kenta Matsuda et al.
SCIENCE IMMUNOLOGY (2019)
Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
Anna Stedman et al.
NPJ VACCINES (2019)
Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models
Qiang Guo et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques
Yupeng Feng et al.
EMERGING MICROBES & INFECTIONS (2018)
A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting
Tiphany Chrun et al.
NPJ VACCINES (2018)
A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test
Paul J. Wichgers Schreur et al.
JOURNAL OF VIROLOGICAL METHODS (2017)
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu et al.
LANCET (2017)
Rift Valley fever virus and European mosquitoes: vector competence of Culex pipiens and Stegomyia albopicta (=Aedes albopictus)
M. Brustolin et al.
MEDICAL AND VETERINARY ENTOMOLOGY (2017)
The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages
Jingyuan Liu et al.
EMERGING MICROBES & INFECTIONS (2017)
Current Status of Rift Valley Fever Vaccine Development
Bonto Faburay et al.
VACCINES (2017)
Rift Valley Fever
Amy Hartman
CLINICS IN LABORATORY MEDICINE (2017)
Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits
Azhar Choudhry et al.
VACCINE (2016)
Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths
Birgit Makoschey et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever
George M. Warimwe et al.
SCIENTIFIC REPORTS (2016)
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Feng-Cai Zhu et al.
LANCET (2015)
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults
Christopher A. Green et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
Daphne A. Stanley et al.
NATURE MEDICINE (2014)
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study
Marc Gurwith et al.
LANCET INFECTIOUS DISEASES (2013)
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
George M. Warimwe et al.
VIROLOGY JOURNAL (2013)
A Single Immunization with MVA Expressing GnGc Glycoproteins Promotes Epitope-specific CD8+-T Cell Activation and Protects Immune-competent Mice against a Lethal RVFV Infection
Elena Lopez-Gil et al.
PLOS NEGLECTED TROPICAL DISEASES (2013)
Tissue Tropism and Target Cells of NSs-Deleted Rift Valley Fever Virus in Live Immunodeficient Mice
Celine Gommet et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Molecular Epidemiology of Rift Valley Fever Virus
Antoinette A. Grobbelaar et al.
EMERGING INFECTIOUS DISEASES (2011)
Present and future arboviral threats
Scott C. Weaver et al.
ANTIVIRAL RESEARCH (2010)
Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR-/- mice induced by different DNA vaccination regimens
Gema Lorenzo et al.
VACCINE (2010)
A Complex Adenovirus-Vectored Vaccine against Rift Valley Fever Virus Protects Mice against Lethal Infection in the Presence of Preexisting Vector Immunity
David H. Holman et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Replicating and non-replicating viral vectors for vaccine development
Marjorie Robert-Guroff
CURRENT OPINION IN BIOTECHNOLOGY (2007)
Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of rift valley fever virus
Brian H. Bird et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Germinal-center organization and cellular dynamics
Christopher D. C. Allen et al.
IMMUNITY (2007)
Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn rift valley fever vaccine
B Botros et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene
T Ikegami et al.
JOURNAL OF VIROLOGY (2006)
Adenoviruses as vaccine vectors
N Tatsis et al.
MOLECULAR THERAPY (2004)
Rift Valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics
TA Madani et al.
CLINICAL INFECTIOUS DISEASES (2003)
Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs
M Bouloy et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
